Canada: Sanofi-Aventis, et al. v. Apotex Inc., et al.

Last Updated: November 25 2014
Article by Adam Bobker and Nathan Haldane

On October 30, the Supreme Court of Canada granted leave to appeal from the Federal Court of Appeal (FCA) decision in Apotex Inc. v. Sanofi-Aventis, et al, 2014 FCA 68.

Sanofi owned a series of patents for the drug Ramipril, the last of which were set to expire in 2005. In anticipation of the expiry, Apotex had received certain regulatory approvals from Health Canada in 2004; however, it did not receive its Notice of Compliance (NOC) until December 12, 2006. This was due to the fact that Sanofi exercised its rights under the PM (NOC) Regulations for a statutory stay of the issuance, which was later found unsustainable. Sanofi acknowledged that Apotex was entitled to damages for the delay but at issue were the relevant dates for computing the loss and the various assumptions and projections built into the assessment of damages.

In order to determine damages, the Trial Judge applied the test from Apotex Inc. v. Merck & Co. , 2011 FCA 329 that requires the Judge to consider the hypothetical question: What would have happened if Sanofi had not brought an application for prohibition? The parties disagreed on the outcome of eight factors that would determine the scope of Apotex's losses. 

In regards to the relevant date for computing the loss suffered by Apotex, the Court looked at all of the Prohibition Orders obtained by Sanofi. Apotex had originally served a notice of allegation in August, 2003, alleging non-infringement of Sanofi's patent. Sanofi then attempted to obtain a Prohibition Order and was successful, effectively blocking the Minister from issuing a NOC. In November of 2003, Apotex filed a second notice of allegation, this time alleging invalidity of the patent. Once again, Sanofi attempted to obtain a Prohibition Order, however this time they were refused by the Court and Sanofi launched an appeal. Before the appeal could be heard, the patent expired and the appeal was dismissed for mootness. The Federal Court found that the second allegation effectively "unlocked" the door for Apotex to receive a NOC and therefore relevant date for assessing damages was the date that the Minister would have issued a NOC, April 26, 2004. 

In assessing the relevant end date for assessing damages, Apotex argued that the correct date was May 2, 2008; the dismissal date of the last Prohibition proceeding. However, the Prothonotary dismissed the Prohibition application as moot, as the NOC had already been issued on December 12, 2006. Sanofi argued that the correct end date was June 27, 2006, the date Apotex ceased to be a "second person" for the purposes of the NOC Regulations. The Court rejected this argument as well, stating that the purpose of S. 8 of the NOC Regulations was to compensate "a second person for the loss occasioned by the operation of the statutory stay." When Apotex received its NOC on December 12, 2006, they could no longer claim to be at a loss and so the Court decided that December 12, 2006 was the relevant end date for assessing damages. The FCA agreed with the Federal Court on both the start and end dates for assessing the liability period. 

The Trial Judge then turned to an assessment of Apotex's lost profits based on what their share of the market would have looked like in a "but, for" world. The Court considered the testimony from experts on both sides and determined what the market for generic Ramipril would have been during the liability period. The Court then turned its attention to assessing what share of the generic market Apotex would have received during the liability period. In considering this, one of the most contentious factors was at what theoretical point other generic manufacturers would have entered the market. Teva had made plans to enter the generic market but was prepared to wait until the expiration of the '457 Patent in December of 2005. Considering the regulatory impediments it would have then encountered, the Trial Judge decided that their date of market entry would have been August 1, 2006. Riva had also made plans to enter the generic market but due to the fact it had cross-referenced its own application to that of Pharmascience and the resulting regulatory hurdles, Riva could not have entered the market until June 21, 2007, after the liability period had expired. Lastly, the trial judge also considered whether an "authorized generic", meaning a drug manufactured by an innovative drug company but sold by a generic company under a generic's name, would have also entered the generic market. The Trial Judge found that it was more likely than not that it would have entered the market, however Apotex's launch would have surprised the innovator and therefore, it would take three months for an authorized generic to enter the market. The Trial Judge selected July 26, 2004 as the likely entry period for the authorized generic. The FCA found that the Trial Judge erred in finding that Teva would have entered the generic market during the liability period, as they found that they would have acted the same in the hypothetical world as they did in the real world. Since they actually did not receive summary dismissal from their Prohibition Applications until December 16, 2006, the FCA found that this is the date they would have entered the generic market, outside the liability period. Therefore, the only competing generic on the market at the time would have been the authorized generic.

The Trial Judge then took the hypothetical entry dates and determined what Apotex's share of the market would have been during the liability period based on who else was in the market. The original Apotex decision had been handed down at the same time as an identical case dealing with what liability Sanofi owed Teva. The Trial Judge divided the generic market based on the hypothetical dates of entry. In the immediate period after Teva entered the generic market, Apotex was to be granted damages representing 70 percent of the market, Teva was to receive 30 percent of the market and the authorized generic would receive 33 percent of the market. Though the Trial Judge accepted that the arithmetic exceeded the total revenue for the market, she rejected Sanofi's argument that there should be only a "single hypothetical market" for the generic product since the "assessment of damages can and should be made on the facts of each case" and that the evidence provided in separate trials led to different conclusions. The majority in the FCA decision agreed and pointed to the fact that the Regulations only expressed that they should be disregarded in constructing one element of the hypothetical generic market. Since it was stated for only one purpose, to read in another would amount to judicially amending S. 8 of the Regulations. 

This methodology was rejected by the minority in the FCA who found that the evidence in both cases was largely the same. The minority found that the proper approach is to construct a hypothetical market that most resembles a real market. In constructing a "real market" the minority found that once a Prohibition Order is refused, the innovating drug company cannot litigate the same issues repeatedly with other generic drug manufacturers. Therefore, it will only be minor regulatory restraints that prevent all the generics from entering the hypothetical real market. This approach creates a "hypothetical market reflecting a level regulatory playing field" and the minority would have sent the matter back to the Federal Court to be re-assessed using these guidelines. 

Also at issue between the parties was whether the "ramp-up" period should be counted twice. A ramp-up period is the time it takes a drug manufacturer to penetrate the market to its full potential. Apotex argued that it already experienced a ramp-up period after they received their NOC, so including a ramp-up period in the damages calculations essentially imposes the penalty twice. The Trial Judge rejected the ramp-up claim because the loss occurred outside of the S. 8 liability period, namely the period of time they were prevented from entering the market. The majority agreed, however the minority would have reversed the Trial Judge's decision to include the second ramp-up period and found that in these cases it is appropriate to exercise discretion and consider the actual ramp-up period as a relevant factor.  

The last issue decided by the Trial Judge and heard on appeal dealt with the so-called HOPE Patents and whether Apotex's compensation could extend to sales of its generic drug for unapproved indications. The drug Ramipril had originally been approved for hypertension; however, further testing revealed it was also beneficial for heart-related health issues and Sanofi had filed two further patents for Ramipril, known as the HOPE Patents, for further uses. The Trial Judge found that some sales of the generic product would have related to the HOPE indications since (a) generic products are not promoted for specific uses, (b) off-label subscribing and substitution commonly take place, (c) Sanofi had not opposed the generic version as being fully interchangeable, and (d) Sanofi could begin an action for patent infringement if they thought it was reasonable to do so. The FCA agreed with the Trial judge and Sanofi's arguments were rejected. 

It is unclear whether the decision on start and end dates will once again be brought before the Supreme Court, however it is clear that the Supreme Court will have to decide the proper way for deciding which generics will enter the market and when they would have done so in a hypothetical world. It will also hopefully clarify what a Court is expected to do when facing more than one trial on for the same patent; create one hypothetical world combining the evidence from both or treat each separately and confine the hypothetical world to the one before the Court.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Adam Bobker
Nathan Haldane
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions